research Serum Interleukin 18 and NLRP3 in patients with Alopecia Areata
Patients with Alopecia Areata have higher levels of certain inflammatory markers.
Search
for
Sort by
Research
90-120 / 1000+ resultsresearch Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research Ovarian sex steroid receptors and sex hormones in androgenized rats
High doses of nandrolone decanoate disrupt ovarian hormones and receptors in rats, with recovery only at lower doses and longer recovery times.
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
research 1446 RNase L acts as a regeneration suppressor
RNase L suppresses regeneration in mammals.
research Early postnatal neuroactive steroid manipulation differentially affects recognition memory and passive avoidance performance in male rats
Changing neuroactive steroids in baby male rats affects their memory and learning differently as they grow up.
research Application of second near infrared fluorescence imaging to trace CelTrac1000-labeled hair follicle epidermal neural crest stem cells in repairing rat facial nerve defects
NIR-II imaging effectively tracked stem cells that helped repair facial nerve defects in rats.
research Correction to ‘Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study’
research Mechanism of action of NLRP3 protein macromolecule based on electrochemical sensors in the treatment of alopecia areata in mice: The role of Ritlecitinib in AA mice through NLRP3
research SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
research Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
research Blood Indices in Patients with Androgenetic Alopecia
Higher NLR, PLR, and MPV may help diagnose androgenetic alopecia.
research Treatment Outcome of Liquid Nitrogen (LN) Cryotherapy in Patients Presenting Recalcitrant Alopecia Areata (AA) at Tertiary Care Hospital, Karachi
Liquid nitrogen cryotherapy worked well for many patients with stubborn alopecia areata.
research 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
research Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study
Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
research The IBHRS Is Up and Running!
The IBHRS is now operational.
research Phase separation: a new window in RALF signaling
LLPS is crucial for RALF signaling, aiding plant growth and stress resilience.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research Clinical and analytical evaluation of LC-MS methods for plasma renin activity and aldosterone
The study developed methods to measure biomarkers in mice and found differences in hormone levels linked to gut microbiota diversity and stress response.
research rwSALT: a regrowth-weighted SALT score providing direct pixel-level measurement rather than visual estimation
rwSALT accurately measures hair regrowth in alopecia areata using scalp photos.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Ritlecitinib is safe and may effectively treat alopecia areata.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research A Comparative Clinical and Trichoscopic Study Between Fractional Radiofrequency Microneedling Versus Intralesional Steroids in Treatment of Alopecia Areata
Fractional radiofrequency microneedling is as effective and safe as intralesional steroids for treating patchy alopecia areata, with fewer side effects.
research LEVERAGING MACHINE LEARNING METHODS IN PREDICTING AND ANALYZING THE ASSOCIATION BETWEEN DIETARY INFLAMMATORY INDEX AND ALOPECIA
Inflammatory diets may increase the risk and severity of alopecia areata.
research Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
research rwSALT: a regrowth-weighted SALT score providing direct pixel-level measurement rather than visual estimation
rwSALT provides precise hair regrowth measurement from scalp photos.